Bone and Soft Tissue TumorsNCT07822204
Molecular and Clinical Studies of Bone and Soft Tissue Tumors
An observational study of Bone and Soft Tissue Tumors, run by Karolinska Institutet at 1 site in Sweden.
Trial summary
The goal of this observational study is to learn whether tumors of bone and soft tissue can be sorted into groups by their genes. Today these tumors are named mainly by how they look under a microscope. There are more than 150 names in use. The same tumor can be given different names by different doctors. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Bone and Soft Tissue Tumors
- How many people
- 50,000 participants
- Where
- 1 siteSweden
- Study dates
- 1 Mar 2026to 1 Mar 2046
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: People of any age with a tumor or tumor-like lesion of bone or soft tissue, benign, intermediate or malignant, diagnosed or reviewed at the Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden. The retrospective cohort is identified from the pathology archive by a predefined search based on the Systematized Nomenclature of Medicine (SNOMED) covering bone and soft tissue tumor codes, with an addendum capturing non-mesenchymal tumors that enter the differential diagnosis, such as melanoma, sarcomatoid carcinoma and lymphoma. The prospective cohort comprises people evaluated at the center during the study period. The center is a national referral center for sarcoma, so the population includes both locally diagnosed and referred cases.
Who may be able to join
- Histopathologically diagnosed tumor or tumor-like lesion of bone or soft tissue, including benign, intermediate and malignant lesions
- Tissue sampled, resected or reviewed at the study center
- Archived diagnostic material available and adequate for the analyses of the relevant cohort: formalin-fixed paraffin-embedded tissue, fresh-frozen tissue, or diagnostic glass slides
- For the prospective cohort, documented informed consent
Who cannot join
- No retrievable diagnostic material or diagnostic report
- Documented objection by the participant to the research use of their material or data
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sweden1 site, 1 recruiting
- Recruiting
Karolinska University Hospital
Stockholm, 17176
Felix Haglund de Flon, MD PhD, Associate Professor, 0046-8-524 800 00, felix.haglund@ki.se
About this study
Official title: Molekylära Och Kliniska Studier av Ben- Och mjukdelstumörer
The goal of this observational study is to learn whether tumors of bone and soft tissue can be sorted into groups by their genes. Today these tumors are named mainly by how they look under a microscope. There are more than 150 names in use. The same tumor can be given different names by different doctors.
The study includes people of any age with a bone or soft tissue tumor. All of them had tissue sampled at Karolinska University Hospital in Stockholm, Sweden.
Read more
The main questions it aims to answer are:
Can tests of a tumor's genes sort these tumors into clearer groups than the names used today? How often does a tumor's gene group differ from the name it was given at diagnosis? Can a computer program tell these groups apart from scanned pictures of the tissue?
Researchers will compare the groups found by the gene tests with the diagnoses given at the time. They will also look at how each group did over the years that followed. This shows which way of sorting tumors better matches what happened to participants.
Participants will not have extra visits, tests, or treatment for this study. The study does not change anyone's care.
Researchers will:
Use tumor tissue that was already taken as part of regular care Read the deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the tumor, which carry its genetic instructions Read the chemical marks on the tumor's DNA that switch genes on and off Scan the glass slides of the tissue into digital pictures Collect facts about treatment and health from medical records
Participants who are newly diagnosed will also be asked for a blood sample. Blood shows which gene changes a person was born with and which ones started in the tumor.
If the study finds a gene change that matters for a participant's care, the study team tells the treating doctors through normal hospital routines.
- Conditions
- Bone and Soft Tissue Tumors
- Keywords
- Sarcoma, Bone and Soft Tissue Tumors, Methylation, Whole Transcriptome Sequencing (WTS), Whole Genome Sequencing (WGS)
- Medical subject headings
- Soft Tissue Neoplasms, Sarcoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group/Cohort 1 - Retrospective archival cohort | People of any age with a bone or soft tissue tumor sampled or resected at the study center before the start of the study, identified from the pathology archive using a predefined search based on the Systematized Nomenclature of Medicine (SNOMED). Diagnostic glass slides are scanned for the full archival cohort. A nested subset with tissue of sufficient quality also undergoes whole genome sequencing, RNA sequencing and DNA methylation profiling. Clinical and outcome data are taken from pathology reports and medical records. No study procedure is performed on participants. Assigned Interventions: Diagnostic Test: Digital pathology and computational image analysis Genetic: Whole genome and whole transcriptome sequencing (nested subset) Genetic: Genome-wide DNA methylation profiling (nested subset) | |
| Group/Cohort 2 - Prospective cohort | People of any age newly diagnosed with, or referred for evaluation of, a bone or soft tissue tumor at the study center during the study period, who consent to the use of their tissue and data. Diagnostic tissue undergoes whole genome and transcriptome sequencing with a matched germline reference sample, DNA methylation profiling and slide digitization. Diagnosis and treatment follow routine practice and are not altered by the study. Assigned Interventions: Diagnostic Test: Digital pathology and computational image analysis Genetic: Whole genome and whole transcriptome sequencing Genetic: Genome-wide DNA methylation profiling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Discordance between molecularly defined class and the original histopathological diagnosis
Proportion of tumors in the molecularly profiled cohort whose class assignment from integrated genomic, transcriptomic and methylation data, made without reference to the diagnostic label, differs from the diagnosis based on the World Health Organization (WHO) classification in the original pathology report. Reported with a 95 percent confidence interval and accompanied by the adjusted Rand index for the full cross-classification. Only assignments above a pre-specified confidence threshold are counted as discordant; low-confidence assignments are reported separately. Discordant cases undergo blinded review by two sarcoma pathologists to separate reclassification from diagnostic error.
Measured: Through completion of the primary analysis of the molecular cohort, up to [5] years after study start.
Secondary outcomes (7)
Number of stable molecular classes identified
Number of classes recovered by consensus clustering of the integrated data that meet pre-specified stability criteria, reported with the stability metrics used (consensus matrix concordance, proportion of ambiguous clustering, cophenetic correlation) across the tested range of cluster numbers.
Measured: Through completion of the primary analysis, up to [5] years.
Proportion of tumors in residual diagnostic categories that receive a defined molecular class
Among tumors originally reported as undifferentiated pleomorphic sarcoma, spindle cell sarcoma not otherwise specified, or an equivalent unclassified bone lesion, the proportion assigned above the confidence threshold to a molecular class that has a defined biological identity.
Measured: Through completion of the primary analysis, up to [5] years.
Accuracy of molecular class prediction from digitized slides
Performance of machine learning models predicting molecular class membership from whole slide images, evaluated in held-out data split at the level of individual participants. Reported as balanced accuracy and macro-averaged area under the receiver operating characteristic curve, with 95 percent confidence intervals, plus per-class sensitivity and specificity.
Measured: Through completion of model development and evaluation, up to [5] years.
Frequency of clinically actionable somatic alterations
Proportion of tumors carrying at least one somatic alteration classified as clinically actionable according to a pre-specified evidence framework, reported by molecular class and by original World Health Organization (WHO) diagnosis.
Measured: Through completion of the primary analysis, up to [5] years.
Frequency of pathogenic germline variants in cancer predisposition genes
Proportion of participants with a matched germline sample carrying a pathogenic or likely pathogenic variant in a pre-specified panel of cancer predisposition genes, classified according to current guidelines.
Measured: Through completion of the primary analysis, up to [5] years.
Overall survival by molecular class
Time from date of diagnosis to death from any cause, with participants alive at last contact censored at that date. Estimated by the Kaplan-Meier method for each molecular class with a sufficient number of participants, and reported with the number of participants per class.
Measured: From date of diagnosis to death from any cause, assessed up to [30] years.
Prognostic information added by molecular class beyond current diagnosis and grade
Comparison of Cox proportional hazards models for overall survival that include molecular class against models that include the original diagnosis and grade, using the concordance index and likelihood-based comparison, adjusted for age, anatomical site, tumor size and treatment.
Measured: From date of diagnosis to death from any cause, assessed up to [30] years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2026
- Study start1 Mar 2026
- Primary completion1 Mar 2046 (estimated)
- Study completion1 Mar 2046 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bone and Soft Tissue TumorsStudies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 50,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Collaborators
- Region Stockholm, Lund University, KTH Royal Institute of Technology, Uppsala University
- Responsible party
- Principal investigator, Felix Haglund de Flon, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07822204
- Sponsor's protocol ID
- 2025-06780-01
- Other IDs
- 2025-03129, 25 4631, 2025
- Status last verified
- Sep 2026
- First submitted
- 10 Sep 2026
- Last updated
- 2 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Individual participant data will not be shared publicly. The data are whole genome sequences, transcriptomes, methylation profiles and whole slide images derived from clinical material. These are personal data under the European Union General Data Protection Regulation and cannot be de-identified to a standard that permits open release, and the ethics approval (Swedish Ethical Review Authority, Etikprövningsmyndigheten, reference number 2025-06780-01) does not cover open publication. Derived and aggregated data supporting the published results, including class assignments, summary variant tables and model performance data, will be published with the primary reports. Requests for access to pseudonymized individual-level data for scientific purposes will be considered by the principal investigator and the responsible organizations, and may be granted where the request is compatible with the ethics approval and applicable law and a data transfer or processing agreement is in place.
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Molekylära Och Kliniska Studier av Ben- Och mjukdelstumörer
- ClinicalTrials.gov ID
- NCT07822204
- Acronym / sponsor ID
- 2025-06780-01
- Conditions
- Bone and Soft Tissue Tumors
- Keywords
- Sarcoma, Bone and Soft Tissue Tumors, Methylation, Whole Transcriptome Sequencing (WTS), Whole Genome Sequencing (WGS)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50,000 participants (estimated)
- Lead sponsor
- Karolinska InstitutetUniversity, hospital or other
- Collaborators
- Region Stockholm, Lund University, KTH Royal Institute of Technology, Uppsala University
- Study start
- 1 Mar 2026 (actual)
- Primary completion
- 1 Mar 2046 (estimated)
- Study completion
- 1 Mar 2046 (estimated)
- First posted
- 16 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn whether tumors of bone and soft tissue can be sorted into groups by their genes. Today these tumors are named mainly by how they look under a microscope. There are more than 150 names in use. The same tumor can be given different names by different doctors.
The study includes people of any age with a bone or soft tissue tumor. All of them had tissue sampled at Karolinska University Hospital in Stockholm, Sweden.
The main questions it aims to answer are:
Can tests of a tumor's genes sort these tumors into clearer groups than the names used today? How often does a tumor's gene group differ from the name it was given at diagnosis? Can a computer program tell these groups apart from scanned pictures of the tissue?
Researchers will compare the groups found by the gene tests with the diagnoses given at the time. They will also look at how each group did over the years that followed. This shows which way of sorting tumors better matches what happened to participants.
Participants will not have extra visits, tests, or treatment for this study. The study does not change anyone's care.
Researchers will:
Use tumor tissue that was already taken as part of regular care Read the deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the tumor, which carry its genetic instructions Read the chemical marks on the tumor's DNA that switch genes on and off Scan the glass slides of the tissue into digital pictures Collect facts about treatment and health from medical records
Participants who are newly diagnosed will also be asked for a blood sample. Blood shows which gene changes a person was born with and which ones started in the tumor.
If the study finds a gene change that matters for a participant's care, the study team tells the treating doctors through normal hospital routines.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group/Cohort 1 - Retrospective archival cohort | – | –People of any age with a bone or soft tissue tumor sampled or resected at the study center before the start of the study, identified from the pathology archive using a predefined search based on the Systematized Nomenclature of Medicine (SNOMED). Diagnostic glass slides are scanned for the full archival cohort. A nested subset with tissue of sufficient quality also undergoes whole genome sequencing, RNA sequencing and DNA methylation profiling. Clinical and outcome data are taken from pathology reports and medical records. No study procedure is performed on participants. Assigned Interventions: Diagnostic Test: Digital pathology and computational image analysis Genetic: Whole genome and whole transcriptome sequencing (nested subset) Genetic: Genome-wide DNA methylation profiling (nested subset) |
| Group/Cohort 2 - Prospective cohort | – | –People of any age newly diagnosed with, or referred for evaluation of, a bone or soft tissue tumor at the study center during the study period, who consent to the use of their tissue and data. Diagnostic tissue undergoes whole genome and transcriptome sequencing with a matched germline reference sample, DNA methylation profiling and slide digitization. Diagnosis and treatment follow routine practice and are not altered by the study. Assigned Interventions: Diagnostic Test: Digital pathology and computational image analysis Genetic: Whole genome and whole transcriptome sequencing Genetic: Genome-wide DNA methylation profiling |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- People of any age with a tumor or tumor-like lesion of bone or soft tissue, benign, intermediate or malignant, diagnosed or reviewed at the Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden. The retrospective cohort is identified from the pathology archive by a predefined search based on the Systematized Nomenclature of Medicine (SNOMED) covering bone and soft tissue tumor codes, with an addendum capturing non-mesenchymal tumors that enter the differential diagnosis, such as melanoma, sarcomatoid carcinoma and lymphoma. The prospective cohort comprises people evaluated at the center during the study period. The center is a national referral center for sarcoma, so the population includes both locally diagnosed and referred cases.
Key inclusion criteria (4 listed)
- Histopathologically diagnosed tumor or tumor-like lesion of bone or soft tissue, including benign, intermediate and malignant lesions
- Tissue sampled, resected or reviewed at the study center
- Archived diagnostic material available and adequate for the analyses of the relevant cohort: formalin-fixed paraffin-embedded tissue, fresh-frozen tissue, or diagnostic glass slides
- For the prospective cohort, documented informed consent
Key exclusion criteria (2 listed)
- No retrievable diagnostic material or diagnostic report
- Documented objection by the participant to the research use of their material or data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Discordance between molecularly defined class and the original histopathological diagnosis
Time frame: Through completion of the primary analysis of the molecular cohort, up to [5] years after study start.
Proportion of tumors in the molecularly profiled cohort whose class assignment from integrated genomic, transcriptomic and methylation data, made without reference to the diagnostic label, differs from the diagnosis based on the World Health Organization (WHO) classification in the original pathology report. Reported with a 95 percent confidence interval and accompanied by the adjusted Rand index for the full cross-classification. Only assignments above a pre-specified confidence threshold are counted as discordant; low-confidence assignments are reported separately. Discordant cases undergo blinded review by two sarcoma pathologists to separate reclassification from diagnostic error.
7 secondary outcomes
Number of stable molecular classes identified
Time frame: Through completion of the primary analysis, up to [5] years.
Proportion of tumors in residual diagnostic categories that receive a defined molecular class
Time frame: Through completion of the primary analysis, up to [5] years.
Accuracy of molecular class prediction from digitized slides
Time frame: Through completion of model development and evaluation, up to [5] years.
Frequency of clinically actionable somatic alterations
Time frame: Through completion of the primary analysis, up to [5] years.
Frequency of pathogenic germline variants in cancer predisposition genes
Time frame: Through completion of the primary analysis, up to [5] years.
Overall survival by molecular class
Time frame: From date of diagnosis to death from any cause, assessed up to [30] years.
Prognostic information added by molecular class beyond current diagnosis and grade
Time frame: From date of diagnosis to death from any cause, assessed up to [30] years.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
- Individual participant dataSharing planned: Undecided. Individual participant data will not be shared publicly. The data are whole genome sequences, transcriptomes, methylation profiles and whole slide images derived from clinical material. These are personal data under the European Union General Data Protection Regulation and cannot be de-identified to a standard that permits open release, and the ethics approval (Swedish Ethical Review Authority, Etikprövningsmyndigheten, reference number 2025-06780-01) does not cover open publication. Derived and aggregated data supporting the published results, including class assignments, summary variant tables and model performance data, will be published with the primary reports. Requests for access to pseudonymized individual-level data for scientific purposes will be considered by the principal investigator and the responsible organizations, and may be granted where the request is compatible with the ethics approval and applicable law and a data transfer or processing agreement is in place.
Related trials for Bone and Soft Tissue Tumors
Active, not recruitingPhase 3
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
Melanoma, Ovarian Cancer
Active, not recruiting
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Bone Metastases, HER2-positive Breast Cancer
Active, not recruitingPhase 3
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone
Active, not recruitingPhase 3
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone
RecruitingPhase 3
Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis
Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bone and Soft Tissue Tumors, run by Karolinska Institutet at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Felix Haglund de Flon, MD PhD, Associate Professor (+46-8-524 800 00, felix.haglund@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Discordance between molecularly defined class and the original histopathological diagnosis (time frame: Through completion of the primary analysis of the molecular cohort, up to [5] years after study start.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026; AzTrials last refreshed its copy on 7 Nov 2026.